Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPLERIXAFOR (plerixafor) by Gland Pharma is cxcr4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (sdf-1α). Approved for combination with filgrastim to mobilize hematopoietic stem cells (hscs) to the peripheral blood for collection, subsequent autologous transplantation in patients with non-hodgkin's lymphoma, multiple myeloma. First approved in 2024.
Drug data last refreshed 18h ago
CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to…
Hematopoietic Stem Cell Mobilizer
Worked on PLERIXAFOR at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo